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 Abstract: 
Background: clinical data on the long-term safety and efficacy of infliximab on psoriatic 
patients who are older than 65 years are limited. 
Objectives: the aim is to report the long-term efficacy, safety and tolerance of infliximab in 
geriatric patients. 
Methods: This was a retrospective study conducted at the Department of Dermatology of the 
University of Rome Tor Vergata. Clinical data were reported at week 12, 52, 104, 208. 
Results: 151 charts were evaluated. A total of 27 patients were included. Range of the age was 
between 65 and 85 years; mean age was 73 years ±5.4; female to male ratio was 1:2; mean age of 
onset of psoriasis was 43 years±17. The average of treatment duration was 39 months ±27 (range 
1-100). Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic arthritis. At 
the baseline the mean PASI score was 15.6 ± 10.2. At week 12, 52, 104, and 208 the mean PASI 
was 2, 2.3, 1.9 and 1.8 respectively. A reduction in the mean PASI was maintained in the long-
term treatment in 12 patients (p<0.001).  
Conclusion: Our data suggest that long-term treatment with infliximab is effective and safe in 
patients over 65 years old and that IV therapy is also associated with a high compliance. 
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 1. Introduction 
Psoriasis (PsO) is a chronic inflammatory skin disease that affects 1-3% of the worldwide 
population. [1] Henseler and Christophers described two clinical presentations of psoriasis, type I 
and II, distinguished by a bimodal age at onset. Type 1 begins on or before age of 40 years; type 
II begins after the age of 40 years. [2] According with different population-based studies, 3.2-
13% of patients experience psoriasis first in their lives over 60 years old, and the proportion 
might increase in aging society. [3-5]
 
 Moreover, it is well known that PsO is associated with 
several comorbidities such as psoriatic arthritis (PsA), metabolic syndrome and cardiovascular 
diseases. [6,7] As the number of individuals older than 65 years continues to rise, psoriasis and 
chronic diseases associated with psoriasis will likely increase in the geriatric population. 
Therefore, dermatologists will face a significant challenge in psoriasis management in older 
adults. However, clinical studies of psoriasis in this specific age group have been rarely 
conducted.  In fact, the elderly are more likely to have arthritis, bone and joint disorders, cancers, 
and other chronic disorders associated with a dramatic impact in quality of life.  
Taking into consideration the comorbidities of a geriatric population of psoriatic patients, 
systemic therapies are often contraindicated. However, few studies and limited clinical trials 
evaluated the safety of conventional and biologic therapies in the treatment of elderly psoriatic 
patients especially in the long term. [8-11]. Among biologics, Infliximab (Remicade®) is a 
chimeric human-murine IgG1k monoclonal antibody, which binds with high affinity, avidity and 
specificity to TNFα approved by the EMA and FDA for the treatment of both PsO and PsA 
[12].This study aims to report our long-term experience on safety, efficacy and tolerance of 
infliximab in elderly patients under treatment with infliximab. 
  
 2. Material and Methods 
A retrospective review of the clinic database at the Department of Dermatology of the University 
of Rome Tor Vergata using the term “infliximab” was undertaken. Using this database-generated 
list, all charts were reviewed identifying psoriatic patients older than 65, treated in the day-care 
unit from 2002 to 2014. 
The baseline characteristics of age, sex, psoriasis phenotype, onset of the disease, comorbidities, 
previous systemic treatments for psoriasis and any concurrent medications were obtained.  
According with the European and Italian guidelines all treated patients were unresponsive or 
contraindicated to at least two systemic conventional therapies. [13]
 
 Patients with infectious 
disease, active or latent tuberculosis (TBC), HIV, neoplastic disease (in the previous 5 years), 
severe heart failure, or demyelinating disorders were excluded. 
Infliximab was administrated intravenously at week 0, 2, 6 and then every 8 weeks. Clinical 
evaluation was assessed at each infusion using the validated psoriasis area and severity index 
(PASI). 
At each infusion, physical examination, standard laboratory tests as well as measure of vital signs 
were assessed. The occurrence of adverse events (AEs) was also investigated and they were 
classified in mild, moderate and severe.  
The safety analyses were performed in all subjects who  received at least one dose of infliximab. 
Laboratory data were recorded by visit descriptively and normal ranges pre-treatment versus 
post-treatment was provided.  
2.1. Statistical analysis: Data from the clinical laboratory analyses were entered into a 
Windows-based database (Microsoft Excel 2007); all statistical analyses were expressed as 
means ± standard deviation (SD). The significance of difference in the mean values obtained at 
T0, W12, 52, 104, and of treatment was assessed with an unpaired Student’s t test (statistical 
significance set at p ≤ 0.05).  
 
3. Results 
A total of 151 charts of patients treated with infliximab during the study period were analyzed. 
Twenty-seven/151 patients met the study criteria for inclusion. The range of the age was between 
65-85 years old, average age 72 ± 5.2, female to male ratio was 1:2 and the mean age of onset 
was 43 years old ±17. Fourteen patients suffered from plaque type psoriasis and 13 from psoriatic 
arthritis. Comorbidities included obesity, hypertension, gastrointestinal and cardiovascular 
diseases, diabetes mellitus, osteoporosis, hypercholesterolemia and thyroid dysfunction are 
reported in detailed in table 1. Three patients were also positive to TB Gold Quantiferon at the 
baseline and prophylaxis was prescribed according with the guidelines. [14] 
The average of treatment duration was 39 months ± 27 (range 1-100 months), with an average 
PASI score of 15.6 ± 10.2. Of those 27 patients, in 7/27 infliximab was the second biologic 
therapy and for 1 patient the third biologic choice. Six patients combined methotrexate from 2 to 
6 months at the dose of 7.5-15 mg/weekly. All patients affected by PsA underwent DMARDs-
based therapy before the first infliximab infusion. Six patients were previously treated with 
methotrexate (7.5-15 mg/weekly) and acitretin (10-30 mg/day), 7 patients with Ciclosporin (3.5-5 
mg/Kg/day) and 3 patients with PUVA therapy. Seven patients had been already treated with 
another biologic drug: Adalimumab (2 patients), Etanercept (3 patients) and Efalizumab (2 
patients).  
At week 12 a reduction in PASI score was observed in 80% of the patients: 4 patients achieved 
(PASI50), 3 patients between PASI75, 5 patients between PASI90 and 13 patients PASI 100 
(Table 2). At week 12, 52, 104, and 208 the mean PASI was 2, 2.3, 1.9 and 1.8 respectively 
(Figure 1). The reduction in the mean PASI score was significant (p<0.001) from week 12 and 
maintained at week 208. Only 2 patients had a worsening of the disease. 
Fifteen/27 discontinued the treatment for the following reasons: 6 patients for lack of efficacy 
(between week 38 and week 78), 2 continued the infusions in a different hospital, and 3 for 
adverse events. Adverse events are described in table 3 and those leading to discontinuation 
included TBC reactivation (n=1 at week 86), surgical operation (n=1 at week 54) and 
spondylodiscitis (n=1 at week 30).  
Infusions reactions were mild and led to treatment discontinuation in 2 patients at week 14 and 
week 46 (orticarioid reaction and uncontrolled arterial hypertension). 
Twelve patients are currently under treatment (>100 months therapies) showing efficacy and 
maintenance of PASI75 in the long-term (p<0.001) associated with a safety profile. 
4. Discussion 
In this article we report evidence of long-term safety and efficacy of infliximab in elderly 
psoriatic patients. To our knowledge, few clinical researches were focused in studying geriatric 
psoriatic patients under treatment with biologics in particular with infliximab. [8-11]
 
 A previous 
retrospective study performed from our group evaluated the long-term efficacy and safety profile 
of subcutaneous  etanercept and adalimumab, in the treatment of elderly patients affected by 
plaque-type Pso and PsA. [10] The study population of Esposito et al. [10] comprised total 89 
patients: 61 patients treated with etanercept and 28 patients treated with adalimumab. The authors 
reported that the main comorbidities associated with psoriatic patients were PsA, cardiovascular 
conditions, and metabolic abnormalities.  They showed that in elderly both treatments were 
effective and the proportion of patients achieving PASI50 was 91.80 and 82.14% at week 156 
with etanercept and adalimumab treatment, respectively, while the proportion of patients 
achieving PASI75 was 83.61 and 71.43% at week 156 when treated with etanercept and 
adalimumab, respectively. Similarly to our observation, treatment adherence and safety profile 
were good. Similarly, Megna et al. [11] reported the efficacy and safety of ustekinumab in a 
group of 22 elderly patients with psoriasis over a 2-year period showing that PASI75 was reached 
by over 90% of patients at week 100.  
In our study we reported in 27 elderly patients under treatment with infliximab a rapid PASI 
score reduction and these results were maintained in the long-term in 12 patients without 
discontinuation.  Infusion reactions were mild. Several studies have shown the efficacy and 
safety profile of infliximab in plaque-type psoriasis,  PsA, pustular and  erytrodermic psoriasis as 
monotherapy or in combination with Methotrexate in children and adults. [15-17] In our 
experience, infliximab was safe in the long-term  as monotherapy or  in  combination with 
Methotrexate.  The safety profile should be a primary need especially in elderly patients in whom 
the comorbidities should be taken into consideration when a treatment is proposed, for the higher 
risk of side effects and drug interactions. The frequent association with other major comorbidities 
requires efficacious treatment options that can be safely administered on a long-term period. 
Moreover, adherence to therapies is a primary determinant of treatment success and physicians, 
and nurses have a key role to improve patient medication adherence in geriatric patients that need 
short hospitalization for infliximab infusions. A survey that asked which route of administration 
for anti-TNF therapy was preferred by patients with rheumatoid arthritis indicated a preference 
for IV administration (that is, with infliximab) over a subcutanoeus regimen [18]. In this survey, 
factors for this preference included patients' general dislike of subcutanoeus injections, pain and 
irritation at the injection site, more frequent administration of the subcutanoeus -administered 
drug , difficulty in handling secure medication containers, and the clinical assistance attendant on 
IV administration. [18] In fact, in our experience IV dosing allows continuous dosage 
adjustments to be made, affording flexibility in matching patient needs at any given time during 
the infusion, helping to optimize overall treatment outcomes, appropriate monitoring and early 
diagnosis of comorbidities (i.e. blood pressure is continuously monitored during the infusions, 
blood exams are performed at each infusion). The latter could be related to the safety profile 
observed in our elderly population. 
  
Even if in a small cohort of patients, our data suggested that infliximab is well tolerated, safe, and 
effective in the long term in treating elderly patients affected by psoriasis or psoriatic arthritis 
despite common comorbidities occurring in an over-65 years old population. The IV therapy was 
also associated with a high compliant profile and the hospitalization and the monitoring of vital 
signs as well as the clinical visit assessed at any infusion can lead to early diagnosis of 
comorbidities. 
5. Expert opinion 
In elderly patients the chronic nature of the disease and the association with other major 
comorbidities  requires efficacious treatment options that can be safely administered on a 
continuous long term basis. In contrast to subcutaneous drugs, the IV therapy allows a constant 
and continuous evaluation  of patients’ comorbidities and possible adverse events by radiological 
exams, blood tests, and measurement of vital parameters. The latter were taken at each infusion 
leading to early recognition of undiagnosed cardiovascular diseases (i.e. hypertension), 
pneumological conditions (i.e. COPD), infections or even cancers. However, since elderly 
minorities have low clinical trial participation in psoriatic population,  our limited experience 
suggests that infliximab is safe, effective  and associated with a high compliance in the long term. 
Finally, effectiveness and safety outcomes appear to be comparable between intravenous and 
subcutaneous anti-TNF-alpha agents in elderly patients with PsO and PsA. 
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 Table 1. Comorbidities   
Co-morbidities   
Arterial hypertension 10 
Cardiovascular disease 5 
Diverticulum 4 
COPD 4 
Gastrointestinal disease 4 
Monoclonal Gammopathy 4 
ΤΒ Gold Quantiferon + 3 
Artrosis 3 
Diabetes Mellitus type II 2 
Hyperlipidemia/Hypercholesterolemia 1 
Prostate Hypertrophy  1 
Cerebrovascular ischemia 1 
Hemorrhoids 1 
Glaucomas bilateral 1 
Depression syndrome 1 
Anxiety 1 
 
 
Table 2. per cent of reduction in PASI score at week 12 
 
                        
27 Patients Reduction PASI <50% 4  
 Reduction PASI ≥ 50%  < 75% 3 
 Reduction PASI ≥75%  < 90% 5 
 Reduction PASI ≥ 90% 13 
 Increase PASI 2 
 
 
 
 
Table 3. Adverse events during the treatment 
ADVERSE EVENTS   
Flu like syndrome 12  
Hypertension 4    
Candidiasis  5   
Cystitis   2   
Herpes Zoster  2   
Basal cell carcinoma  2    
Hyperlipidemia 1   
Diarrhea   1   
Lithiasis Uterus bladder 1   
Perianal fistula 1    
Headache    1   
Irregular profile gamma 1    
 
 
 
 
Figure 1: The graph  shows the mean PASI score at baseline, week 12, 52, 104 and 208 of 12 
patients that were treated with infliximab in the long term without discontinuation. 
 
 
 
